Product Description
Mechanisms of Action: Btk Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Spebrutinib](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Arthritis, Rheumatoid
Phase 1: Healthy Volunteers|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Waldenstrom Macroglobulinemia|Lymphoma, B-Cell|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Lymphoma, Non-Hodgkin
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CC-122-DLBCL-001 | P1 |
Terminated |
Follicular Lymphoma|Diffuse Large B-Cell Lymphoma |
2023-12-12 |
|
CC-292-CLL-001 | P1 |
Completed |
Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia |
2019-01-23 |
47% |
CC-292-RA-001 | P2 |
Completed |
Arthritis, Rheumatoid |
2016-01-01 |
|
CC-292-CLL-002 | P1 |
Completed |
Chronic Lymphoid Leukemia|Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia |
2015-12-01 |